CD274 and neoplasm: Mesothelioma has very low tumor mutational burden (TMB) and low PD-L1 expression which make it less responsive to the checkpoint inhibitor treatment [71] although checkpoint blockade is included in NCCN guideline as a second line of therapy due to limited treatment options for mesothelioma patients.